Loading
A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. is a phase 1 interventional study registered as NCT03774056 by Hinova Pharmaceuticals Inc., with 43 participants enrolled, started 2017-02-10. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: HC-1119.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/